Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | A novel composite endpoint of toxicity and PFS in patients with R/R FL treated with axi-cel

Razan Mohty • 25 Apr 2023
EBMT 2023
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel
ZUMA-5

Razan Mohty, MD, Moffitt Cancer Center, Tampa, FL, summarizes the key points of a study evaluating a novel composite endpoint of toxicity and progression-free survival (PFS) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with axicabtagene autoleucel (axi-cel). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Razan Mohty

2:00
Utilizing cytokine profiles at baseline to predict cytopenia after treatment with ide-cel
Razan Mohty • 25 Apr 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals